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Acute renal failure withpreserved renal plasma flow induced by cancer
immunotherapy. Adoptive immunotherapy in patients with advanced
cancer produces significant regression of metastatic disease in selected
patients, but it is complicated by severe side effects. Prevention of these
complications is still limited because their precise mechanisms remain
unknown. For this reason we have investigated renal function and
hemodynamic parameters in 16 patients with renal cell carcinoma
before and during treatment with a combination of high doses of both
recombinant interleukin-2 (rIL2) and recombinant a-interferon. After
patients had received three injections of combined immunotherapy,
there was a decrease in mean blood pressure (—20%), glomerular
filtration rate (—25%), urine output (—50%), and fractional sodium
excretion (—0.8%). This was associated with an increase in heart rate
(+30%), plasma creatinine level (+30%), fractional potassium excretion
(+ 14%) and microalbuminuria (+ 130%). However, renal plasma flow
remained constant. The increment in microalbuminuria may reflect an
alteration of glomerular capillary permeability. The reduction in GFR
may be accounted either for a decrease in efferent to afferent arteriolar
resistance ratio, leading to a decrease in glomerular capillary pressure,
or for a decrease in ultrafiltration coefficient, or both. Nonsteroidal
antiinflammatory drugs, such as ketoprofen, used to minimize side
effects, could considerably worsen renal function and should be
avoided in patients treated by rlL2. Our results bring new insights into
the pathogenesis of functional acute renal failure and provide a rational
basis for the use of vasopressors in the treatment of cytokine-induced
acute renal failure.
Recent progress in cellular immunology combined with de-
velopments in biotechnology have provided new opportunities
for immunotherapy in the treatment of end stage cancers in
humans. Recombinant interleukin 2 (rIL2) alone or in combi-
nation with recombinant alpha-interferon (a-IFN) or lympho-
kine activated killer cells (LAK cells) were shown to mediate
the regression of some metastatic tumors [1, 2]. However,
severe side effects involving multiple organ systems are asso-
ciated with the administration of rIL2. Patients have to be
admitted to intensive care units, and sometimes rIL2 treatment
must be withdrawn because of clinical intolerance. One of the
major side effects is acute renal failure (ARF), which has been
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regarded as functional in its mechanism [3—8], although its
precise mechanisms remain elusive. Studies on renal hemody-
namics in ARF are rare in humans. ARF during rIL2 therapy
provides an unique opportunity of studying the kinetics of
cytokine-induced changes in renal hemodynamics.
Somewhat empirical strategies have been developed to coun-
teract side effects in these patients. Fever and chills can be
alleviated by administering nonsteroidal antiinflammatory drugs
which are potent inhibitors of prostaglandin synthesis. How-
ever, these drugs are known to impair renal function [9]. On the
other hand, the use of steroids was reported to avoid side
effects, but it may also abrogate the therapeutic effects on
cancer [10]. Thus, a better understanding of the physiopatho-
logical mechanisms would lead to a more rational therapeutic
approach. For this purpose we investigated renal function in 16
patients undergoing immunotherapy.
Methods
Patients
Sixteen patients (13 males, 3 females) aged 56 7 years with
metastatic renal cell carcinoma were admitted to the intensive
care unit. Thirteen patients had undergone unilateral nephrec-
tomy at least six months prior to the study. Patients with
Karnofsky scale below 80%, active systemic infection, central
nervous system metastases or major medical illnesses of car-
diovascular or respiratory systems were excluded. The protocol
was reviewed and accepted by the ethical committee (Univer-
site Claude Bernard et Hospices civils de Lyon). Patients had
given full informed consent to immunotherapy with rIL2,
a-IFN and LAK cells. Additional informed consent was ob-
tained from each patient before any renal monitoring.
Immunotherapy
Patients received rIL2 (Eurocetus) (72 million U/m2/day) and
cs-IFN (Unicet) (IS million U/m2/day) as a 30 minute intrave-
nous infusion at eight hour intervals for six consecutive days.
After a six-day rest, they received a second cycle consisting of
a combination of cytokines for five days. Lymphocytes were
obtained via repeated leukophereses for generation of LAK
cells. These cells were placed in suspension and administered
during the second cycle (on days 13, 14 and 16). Patients
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received the following concomitant medications in attempt to
minimize side effects: primarily ketoprofen (100 mg every 8
hours) and paracetamol (1 g every 8 hours) to control fever,
alizapride (25 mg every 8 hours) as symptomatic treatment for
vomiting and diarrhea, oral misoprostol (200 mg every 8 hours)
for prophylaxis against gastrointestinal bleeding and prophylac-
tic antibiotherapy (cefmenoxin: I g thrice daily). Volume ex-
panders (5% albumin solute: 27 17 g in 14 patients) were
administered when necessary to avoid hemodynamic instability
(central venous pressure was maintained from 1 to 5 cm H,O).
Vasopressor therapy with dopamine hydrochloride up to 5 ig
min' kg1 is usually used in these patients, but to avoid renal
hemodynamic interference, this drug was not infused during the
first day of immunotherapy.
Renal function studies
Urinary flow rate [VJ, inulin clearance [C1] as glomerular
filtration rate (GFR), PAH clearance [CPAHI as renal plasma
flow (RPF), fractional Na and K excretion EFENa and FEK] and
microalbuminuria [Alb] were studied before and one day after
the onset of therapy (three injections of rIL2 and a-IFN).
Plasma creatinine [Per] was measured before, after one day of
treatment, at the end of cycle and just before the beginning of
second cycle (day 11). Inulin and PAH clearances were deter-
mined by the continuous infusion technique described previ-
ously [11]. Na and K concentration were measured by flame
photometry and creatinine by an automated method adapted
from Jaffé's reaction. Alb was determined by immunotur-
bidimetry. Blood pressure (BP) and heart rate (HR) were
continuously monitored with an oscillometric method. FENa
and FEK were calculated according to standard formula. Renal
vascular resistances (RVR) were evaluated by the following
formula: [mean BP x (1 — hematocrit)]/CPAH.
Statistical analysis
Clearances and clinical data were averaged over two sequen-
tial, thirty minute periods. Paired nonparametric test (Wilcoxon
signed rank test) was used to compare pre- and post-treatment
data. The Mann-Whitney test was used to compare unpaired
data between the two groups. Results are presented as mean
SD.
Results
All patients were studied before and after administration of
three injections of rIL2 and a-IFN. Evident criteria of ARF
appeared on the first day of immunotherapy: there was a
significant increase in Cr from control (113 21 jsmol/liter) to
day 1 (149 37 mol/liter; P < 0.001). At the end of cycle on
day 6, 1Cr reached 286 168 mol/liter (P < 0.001 vs. control).
At day 11, 'Cr (108 62 mol/liter) was not different from the
control level. After the first day of immunotherapy there were a
significant decrease in mean BP (—18%; P < 0.001) and an
increase in HR (30%; P < 0.01). Figure 1 depicts individual pre-
and post-treatment values of C1, CPAH and filtration fraction
(FF). In all but one patient C1 decreased after one day of
immunotherapy, whereas CpAH was reduced in only four pa-
tients. FF did not vary in one patient and fell in all the remaining
patients. On the average (Table 1), C1 was decreased by 26%
(P < 0.01), whereas there was no significant change in CPAH (P
= 0.056), leading to a significant decrease by 38% in FF (P <
0.001). Figure 2 represents the influence of immunotherapy on
the correlation between C1 and CPAH: for a given level of
CPAH, C1 is lower after treatment. The constancy of CPAH
associated with the significant decrement in mean BP accounted
for the significant decrease by 33% in RVR (P < 0.01). As for
renal excretory patterns, there was a marked fall in both urinary
output (—50%, P < 0.01) and FENa (P < 0.02) associated with
an increase in FEK (P < 0.02). Microalbuminuria, which was
within normal limits prior to therapy, increased more than
twofold during the first day of treatment (P < 0.001).
To analyze the effects of non steroidal antiinflammatory drugs
on renal function, patients were divided into two groups: group
I with ketoprofen and group 2 without ketoprofen during the
first three injections of rIL2 and a-IFN. Initially there were
eight patients in each group. Unfortunately, this protocol with
high dose of cytokines, the severity of side effects (mainly chills
and fever) required the use of ketoprofen in some patients of
group 2, so that only four patients did not actually receive this
P 0056 0.0007150
125
E 100
75
E50
25
0
1250
1000
R
750
E
500
0
C)a
C0
Cu
CL
0.40
0.32
0.24
0.16
0.08
0.00
250
Control lL2 IFN
0
Control 1L2 - FN
Fig. 1. Individual renal hemodynamic data
__________________
before and 24 hours after the initiation of
cytokines treatment in 16 patients with renal cell
Control 1L2 + EN carcino,na. (Wilcoxon paired test).
Mercatello et a!: Cytokine nephrotoxicity 311
Table 1. Renal function and hemodynamic da ta before and during interleukin 2 therapy in all patients
Before During Percent
IL 2 therapy IL 2 therapy Change P
Weight kg 67.7 14.5 67.8 14.2 0 NS
Mean BP mm Hg 94 13 77 14 —18 0.0009
Heart rate pulses/mm 72 10 92 19 28 0.002
C1,, ml/min/1.73 m2
CPAH ml/min/l.73 m2
81 21
398 98
60 28
482 204
—26
21
0.003
NS (0.056)
RVR mm Hg/mI/mm 0.17 0.05 0.12 0.04 —33 0.003
Ht 0.35 0.06 0.35 0.06 0 NS
FF 0.205 0.031 0.127 0.039 —38 0.0007
V mI/mm 2.7 1.0 1.4 0.6 —48 0.002
pAlb mg/100 mg creatinine 6.1 13.7 14.0 19.2 129 0.0007
FENa % 1.37 0.48 0,56 0.35 —0.81 0.018
FEK % 12.41 2.94 26.69 11.94 14.28 0.018
Abbreviations are: BP: blood pressure; C1,,, inulin clearance; CPAH, paraaminohippurate clearance; RVR, renal vascular resistances; Ht,
hematocrit; FF, filtration fraction; V, urinary output; Alb, microalbuminuna; FENa and FEK, fractional excretion of sodium and potassium,
respectively.
a Wilcoxon paired test.
medication. Data were then compared between group I patients
who received ketoprofen (N = 12) and group 2 (N = 4) who
were not given this medication. Control data of each group are
recapitulated in Table 2. After three infusions of cr-IFN and
rIL2, there were no significant differences between patients
from group I and group 2 in the percent change in weight
(+0.3% and 0, respectively), mean BP (—20% and —19%), HR
(+27% and +32%), C1,, (—32% and —10%), FF (—35% and
—40%) and Alb (+ 128% and + 207%). In contrast, the percent
increase in CPAH (+6% and +59%) was significantly higher (P
< 0.01) and the percent decrease in RVR (—29% and —48%)
was significantly greater (P < 0.02) in group 2 compared to
group 1. Figure 3 shows the percent change in GFR and CPAH
in the two groups after immunotherapy.
Group I Group 2 P
N 12 4
Sex (MIF) 10/2 2/2
Nx I 2
Age years 57.8 6.6 51.3 4.9 NS
Weight kg 68.4 15.2 64.5 14.8 NS
Mean BP mm Hg 95 15 92 8 NS
Heart rate pulses/mm 70 II 77 7 NS
CPAH ml/min/1.73 m2 377 72 458 149 NS
RVR mm Hg/mI/mm 0.18 0.06 0.15 0.05 NS
C1,, mlimin/l.73 m2 76 14 95 33 NS
FF 0.20 0.03 0.20 0.02 NS
Alb mg/lOO mg creatinine 7.6 15.7 1.5 1.6 NS
Albumin solute infused g 32 17 15 10 NS
Discussion
ARF is known to occur frequently during IL-2 therapy [3—8].
The decrease in renal function begins immediately after the
initiation of therapy and the magnitude of worsening is contem-
porary with the end of cytokine infusion. A rapid return to
control values is noted following discontinuation of treatment.
Numerous medications have to be used as symptomatic support
in the course of immunotherapy. Among them, only paraceta-
mol may in some rare conditions cause acute tubular necrosis
[12]. Cefmenoxin, a third generation cephalosporin, and aliza-
pride have not been described to produce alteration in renal
function. Misoprostol, an analogue of prostaglandin E1, is not
known to possess renal effects [13]. Alpha-IFN alone has been
rarely reported to induce renal impairment [141. The most
common manifestation is proteinuria, which is found in 15 to 20
percent of patients receiving IFN [15]. This proteinuria is
usually mild, but a nephrotic syndrome has also been reported
[16]. Experimental animal models have shown that renal toxic-
ity of IFN is manifested essentially by glomerular alterations
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Fig. 2. Correlation between para-aminohippurate clearance and inulin
clearance (GFR) before treatment (E1J) and after I day of rIL2 and YJFN
infusions (A). Linear regressions are: Control: y = 8.1 ÷ 0.18x; r =
0.85; P < 0.001; Treatment: y = 9.7 + 0.lOx; r = 0.77; P < 0.01.
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[17, 18]. There are no data available on a renal hemodynamic
effect of a-IFN alone nor on a worsening effect of a-IFN on
rIL2 induced ARF. However, one cannot exclude its participa-
tion in the pathogenesis of ARF.
There is a large agreement about the physiopathological
mechanism of rIL2-induced ARF which is considered to be
mainly functional. In our patients, the observed decrease in
GFR, V together with the fall in FENa, and the increase in FEK
are actually the hallmark of a functional ARF. The mechanism
of prerenal ARF is usually attributed to a decrease in renal
blood flow and GFR consecutive to hypovolemia and/or hypo-
tension [19, 20]. Change in intravascular volume as a conse-
quence of vomiting and diarrhea is improbable since in our
patients body weight was unchanged. Hemodynamic data are
more likely compatible with another mechanism described in
patients treated by rIL2: the so-called "capillary leak syn-
drome." The increased capillary leakiness to macromolecules
induces an increased interstitial volume to the detriment of the
intravascular spaces, leading to hypovolemia. The latter mech-
anism, associated with the decreased vascular resistances,
induces consistently a drop in mean arterial pressure with a
compensatory increase in cardiac output and heart rate [21, 22].
However, the most striking result is the lack of any significant
decrease in CPAH. One previously published report showed a
decrease in RPF in such condition, but this study was per-
formed in only one patient [5]. Another recent report described
similar results of a functional ARF with preservation of RPF on
the fourth day following initiation of rIL2 therapy [23]. But in
this study, RPF was measured by clearance of It31 hippuran
which is known to give an overestimate of RPF by about 10% to
15%. Moreover, GFR was assessed by creatinine clearance
which has long been known to be an imprecise measure of GFR,
especially in the case of renal impairment. Even in CPAH is not
an accurate index of RPF in these situations [24], because the
decreased extraction leads to underestimated RPF, the fact that
there was no significant change in CPAH suggests that RPF
remained at least at control levels, but might actually be even
higher. The constancy of CPAH despite the reduction of mean
BP highly accounted for the drop in RVR. In this context, the
isolated reduction in GFR might be interpreted as a decrease in
efferent to afferent arteriole resistances ratio. This situation had
to lead to a reduction in intracapillary glomerular pressure. In
favor of this mechanism, we recently reported that norepineph-
rime infusion, which is known to enhance RVR [25], improved
creatinine clearance in patients undergoing rIL2 therapy [26].
However, the lack of initial alteration in RPF suggest that other
pathophysiological factors may be involved to account for the
decrease in GFR, Some reports suggest that a similar mecha-
nism might occur during treatment of hypertension with renal
artery stenosis by converting enzyme inhibitors [27]. But this
clinical situation is different from rIL2 nephrotoxicity, as in
response to the decreased RPF below the stenosis, there is a
compensatory response of the renin-angiotensin system to
maintain GFR by increasing efferent arteriole resistances. Ad-
ministration of converting enzyme inhibitor blocks this angio-
tensin compensatory response, which results in a dramatic drop
in GFR. During rIL2 therapy, RVR and GFR decreased despite
the reported increase in plasma renin activity [5], probably in
response to hypotension. Likewise, there is some information
regarding the similarity of rIL2 therapy to sepsis [28, 29]. In
numerous experimental studies of septic shock, RPF has been
shown to be preserved, at least in the early phase [30, 31].
However, these studies did not bring precise information about
renal function and especially GFR. In one study performed in
dogs [32], GFR did not vary during the onset of sepsis, and
polyuria with increased sodium excretion rather than oliguria
and sodium retention were reported. For understandable rea-
sons, there were no data available in humans.
Another interesting result in this study is the significant
increase in j.tAlb during rIL2 and a-IFN treatment. Increments
in pAlb are usually attributed to an increased intracapillary
glomerular pressure or an alteration of the glomerular wall
permeability [33]. The former mechanism is unlikely to explain
Alb in our patients, because of the probable reduction in
intracapillary glomerular pressure, but a direct alteration of the
glomerular capillaries may be considered as a renal manifesta-
tion of the generalized capillary alteration [341. A further
indirect evidence for this mechanism is in reports of a nephrotic
syndrome in a patient treated by rIL2 [35] or aIFN [16].
Finally, in some experimental models of acute glomerulone-
phritis [36], it has been demonstrated that the combination of
albuminuria and reduced GFR could be explained by a reduc-
tion in ultrafiltration coefficient (Kr). In this view, immunother-
apy induced ARF may be brought about by a similar mecha-
nism, and may be considered as a "glomerular" functional ARF
rather than an "ischemic" functional ARF.
Nonsteroidal antiinflammatory drugs (NSAD), such as keto-
profen, are commonly used to minimize side effects during rIL2
and a-IFN therapy. These drugs are known, via their prosta-
glandin inhibiting properties, to decrease RPF [37]. Among the
16 patients, four did not receive ketoprofen (group 2) and the
remaining 12 patients received ketoprofen (group 1). Although
not significantly, renal function was higher in group 2 compared
to group 1, because two patients in the former group and only
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Fig. 3. Percent changes in GFR (squares) and PAH clearance (trian-
gles) in patients with ketoprofen (group 1: open figures) and in patients
without ketoprofen (group 2: closed figures) before (Control) and after
3 injections of recombinant interleukin-2 and alpha interferon.
(* Mann-Witney test).
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Clinical observations and animal studies suggest that IL-2
mediates changes in capillary permeability and reduction in
systemic vascular resistances either directly [38], or more
likely, indirectly [34] via endogenous cytokine cascade [39]. It
has been reported that rIL2 stimulates endogenous production
of ILl, lymphototoxin, 7IFN and primarily tumor necrosis
factor (TNF) [40]. TNF can produce changes in vascular
permeability by the generation of oxygen free radicals [411.
Complement activation [42] or other vasoactive substances
such as kinins, histamine and serotonin which play a role in
inflammatory responses, may also be involved in these alter-
ations.
Is it possible to alleviate toxic side effects without decreasing
antitumoral efficiency? The use of steroids produce a significant
reduction in vascular permeability [10] but may also abrogate
the therapeutic effects of rIL2 [43]. Steroids block the endoge-
nous cytokine cascade and decrease TNF production, which
has been correlated to the clinical response to rIL2 therapy in
patients with metastatic renal cell carcinoma [44]. In fact, a
recent study in mice showed that passive immunization against
tumor necrosis factor partially abrogates rIL2 toxicity without
deleterous effect on antitumor action [45].
Pressor support, such as dopamine hypochloride, phenyleph-
rifle hypochioride or norepinephnne, are effective in improving
arterial pressure in patients receiving rIL2 [21, 221. Some
studies have reported significant improvement of renal function
during dopamine infusion in ARF [46] by decreasing renal
vascular resistances primarily on preglomerular vessels [47].
However, such an effect cannot be evidenced during rIL2
therapy [26]. As we previously suggested, during rIL2-induced
ARF there was a drop in RVR. Thus a further reduction in RVR
with pharmacological agents might be inefficient and might
cause additional damage to tubules and glomeruli. On the other
hand, potent vasoconstrictor agents might be useful in this
clinical situation, as suggested by a recent preliminary report
[26].
In conclusion, results which showed a preservation of RPF
and a solitary drop in GFR provide a new insight into the
pathogenesis of such an ARF and a further rational basis to the
use of vasoactive agents in the treatment of rIL2-induced ARF.
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